We have written an open letter to the pharmaceutical and food and drink industries warning firms that they should not capitalise on the current situation by charging unjustifiably high prices for essential goods or making misleading claims around their efficacy.

We are prepared to use all of the powers available to us to ensure that markets continue to work well during the coronavirus outbreak.

Read our news story for more information: COVID-19: sales and pricing practices during Coronavirus outbreak.